. Author manuscript; available in PMC: 2022 Feb 1.

Published in final edited form as: J Natl Med Assoc. 2020 Jul 28;113(1):8–29. doi: 10.1016/j.jnma.2020.07.001

Table 1.

Inclusion criteria for the review

Category	Criteria
Population	Black adults or children (including study-defined, self-reported or defined in-study via genetic ancestry approaches (e.g., genotyping ancestry informative markers, using the program STRUCTURE)) receiving pharmaceutical agent(s) of interest, short or long acting β₂ agonists.
Publication languages	English only
Admissible evidence (study design and other criteria)	Admissible designs Analyses of racial/ethnic response variation: systematic reviews, meta-analyses, database or registry studies, comparative studies (randomized controlled trials (RCTs), prospective or retrospective cohort studies, case series) Clinical trials with racial/ethnic subgroup analyses: RCTs, prospective or retrospective cohort studies, case series
	Other criteria Original research studies providing sufficient detail regarding methods and results to enable use and aggregation of the data and results
	Studies must have relevant population Studies must address one or more of the following: -Analyses of therapeutic response by race/ethnicity -Analyses of safety by race/ethnicity Studies must include comparison with at least one other race/ethnicity group Relevant outcomes must be able to be extracted from data in the papers Study published January 2000 – July 2019^*

Legend: This table describes the detailed criteria the team employed to select literature for inclusion in this review. The year 2000 was selected as a start date based on the rationale that pharmacogenomics analyses were likely to be rare before this date.